API | foliglurax

foliglurax Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4), which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. It reached phase II clinical trials, but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints. ^Wikipedia

Chemistry

SMILES: O/N=c1\cc(-c2cc3sccc3cn2)oc2ccc(CCCN3CCOCC3)cc12
InChIKey: ZTEDNASHAWNBKQ-NCELDCMTSA-N
Mol. Mass: 421.52
ALogP: 4.26 Partition coefficient
ChEMBL Molecule:
foliglurax

More Chemistry

Pharmacology

Mechanism of Action:
- Metabotropic glutamate receptor 4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

foliglurax | pxt002331

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Healthy Volunteers (Phase 1)

Parkinson Disease (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue